BioSpace News Archive

Genetown

Avenge Bio to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Avenge Bio, Inc. today announced their poster presentation at the Society of Immunotherapy of Cancer 38th Annual Meeting (SITC 2023) on November 1-5, 2023, in San Diego, California.

October 24, 2023
·
3 min read
Genetown

New Study Published in Cardiovascular Digital Health Journal Shows Implicity’s Algorithm Significantly Reduces AF Alert Burden in Remote Cardiac Monitoring

Implicity, a leader in remote patient monitoring (RPM) and cardiac data management solutions, today announced the results of a clinical study published in the Cardiovascular Digital Health Journal.

October 24, 2023
·
3 min read
Drug Development

Oxular Doses First Patients in OXEYE Phase 2 Clinical Trial of Suprachoroidal OXU-001 as a Long-Acting Treatment for Diabetic Macular Edema

Oxular Limited today announces that it has begun dosing in its OXEYE Phase 2 clinical trial evaluating the company’s lead product candidate, suprachoroidal OXU-001, for the treatment of diabetic macular edema (DME).

October 24, 2023
·
3 min read
Business

Merck Senior Vice President Sarah Aiosa Named to Most Powerful Latinas List

We’re proud to celebrate Sarah M. Aiosa, SVP and president, Latin America, for being recognized as one of The Association of Latino Professionals for Americas’ 2023 Most Powerful Latinas!

October 24, 2023
·
1 min read
Business

Scorpion Therapeutics Appoints Precision Medicine Leader Jeff Albers as Strategic Advisor

Scorpion Therapeutics, Inc. today announced the appointment of Jeff Albers as a strategic advisor to the company.

October 24, 2023
·
3 min read
Genetown

Ankyra Therapeutics Receives FDA IND and Health Canada CTA Approval to Advance First-In-Class Selective Anchored Immunotherapy Agent, ANK-101, into Human Trials in Solid Tumors

Ankyra Therapeutics Receives FDA IND and Health Canada CTA Approval to Advance First-In-Class Selective Anchored Immunotherapy Agent, ANK-101, into Human Trials in Solid Tumors.

October 24, 2023
·
3 min read
Genetown

bluebird bio to Host Third Quarter 2023 Financial Results Conference Call

bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss third quarter 2023 financial results and business updates on Tuesday, November 7 at 8:00 a.m. ET.

October 24, 2023
·
1 min read
Genetown

DermBiont Announces First Close of $35.2 Million in a Series B Financing to Advance First-in-Class Targeted Topical Dermatological Therapeutics

DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today announced a $35.2 million Series B financing, including a $27.1 million Series B first close and $8.1 million in converting outstanding notes.

October 24, 2023
·
4 min read
FDA

MTF Biologics® Receives First Investigational Device Exemption Approval for Human Acellular Dermal Matrix in Breast Reconstruction

MTF Biologics ® Receives First Investigational Device Exemption Approval for Human Acellular Dermal Matrix in Breast Reconstruction.

October 24, 2023
·
3 min read
Business

Day Zero Diagnostics Names Jeff Mirviss Chair of Board of Directors

Day Zero Diagnostics Inc. announced today that independent board member, Jeff Mirviss , has been appointed board chair.

October 24, 2023
·
2 min read